AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31584721 — intervention group
Group type: COMPARATOR
Intervention: Waitlist-Control Condition
Number of subjects: 209
Study 27900849 — intervention group
Group type: EXPERIMENTAL
Intervention: Wristband (WB) and smartphone application (APP) with personalized feedback every 7 days
Number of subjects: 36
Study 27900849 — intervention group
Group type: COMPARATOR
Intervention: Standard approach (low-energy diet and physical activity prescription)
Number of subjects: 36
Study 27270279 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous venovenous hemofiltration (CVVH)
Number of subjects: 16
Study 27270279 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous venovenous hemodiafiltration (CVVHDF)
Number of subjects: 16
Study 27270279 — intervention group
Group type: EXPERIMENTAL
Intervention: High dosing regimens (≥25 mg/kg) and extended intervals (36 to 48 h)
Number of subjects: 16
Study 27270279 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-interval high loading dose of amikacin (25 mg/kg every 48 h) with therapeutic drug monitoring (TDM)
Number of subjects: 16
Study 25705964 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative cognitive-behavioral intervention (CBT) and usual care
Number of subjects: 90
Study 25705964 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 90
Study 24349782 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid 4.0 mg supplementation throughout pregnancy
Number of subjects: 3656
Study 24349782 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3656
Study 20634744 — intervention group
Group type: EXPERIMENTAL
Intervention: Sagittal Plane (SP) Plyometrics
Number of subjects: 32
Study 20634744 — intervention group
Group type: COMPARATOR
Intervention: Frontal Plane (FP) Plyometrics
Number of subjects: 32
Study 17765233 — intervention group
Group type: EXPERIMENTAL
Intervention: EmbryoGlue as the embryo transfer medium
Number of subjects: 0
Study 17765233 — intervention group
Group type: COMPARATOR
Intervention: Standard culture media
Number of subjects: 0
Study 16914390 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 200
Study 16914390 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet and exercise
Number of subjects: 200
Study 16914390 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet and exercise + niacin
Number of subjects: 200
Study 16914390 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet and exercise + fenofibrate
Number of subjects: 200
Study 16914390 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet and exercise + niacin and fenofibrate
Number of subjects: 200
Study 14582814 — intervention group
Group type: EXPERIMENTAL
Intervention: Fexofenadine hydrochloride, 180 mg
Number of subjects: 495
Study 14582814 — intervention group
Group type: COMPARATOR
Intervention: Cetirizine, 10 mg
Number of subjects: 495
Study 10999556 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (TPM)
Number of subjects: 0
Study 10999556 — intervention group
Group type: COMPARATOR
Intervention: Valproate (VPA)
Number of subjects: 0
Study 8997048 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 2.5 mg.kg‐1
Number of subjects: 60
Study 8997048 — intervention group
Group type: COMPARATOR
Intervention: Thiopental 5 mg.kg‐1
Number of subjects: 60
Study 1336008 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin (DDP) administration as monochemiotherapy
Number of subjects: 33
Study 1336008 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin (DDP) administration in combination with glutathione
Number of subjects: 33
Study 4050769 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention program focusing on nutrition, physical fitness, and cigarette smoking prevention
Number of subjects: 2283
Study 30981604 — intervention group
Group type: EXPERIMENTAL
Intervention: IDEA workflow for genomic analysis
Number of subjects: 0
Study 30981604 — intervention group
Group type: EXPERIMENTAL
Intervention: IDEA workflow optimized for circulating tumor DNA
Number of subjects: 0
Study 30981604 — intervention group
Group type: EXPERIMENTAL
Intervention: IDEA workflow
Number of subjects: 0
Study 29369914 — intervention group
Group type: EXPERIMENTAL
Intervention: ANT1 soybean extract cream
Number of subjects: 45
Study 29369914 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 27374944 — intervention group
Group type: EXPERIMENTAL
Intervention: Annual mammography and physical examination (MA + PX) for women aged 40-49
Number of subjects: 89835
Study 27374944 — intervention group
Group type: EXPERIMENTAL
Intervention: Annual mammography and physical examination (MA + PX) for women aged 50-59
Number of subjects: 89835
Study 27374944 — intervention group
Group type: EXPERIMENTAL
Intervention: Including ductal carcinoma in situ with invasive cancer for women aged 40-49
Number of subjects: 89835
Study 27374944 — intervention group
Group type: EXPERIMENTAL
Intervention: Including ductal carcinoma in situ with invasive cancer for women aged 50-59
Number of subjects: 89835
Study 24942055 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine (0.25, 0.75 or 1.25 mg/100 cm² wound size) in hydroxyethylcellulose gel
Number of subjects: 44
Study 24942055 — intervention group
Group type: COMPARATOR
Intervention: Placebo applied onto the excised split-thickness donor wound
Number of subjects: 44
Study 22275444 — intervention group
Group type: COMPARATOR
Intervention: Metformin monotherapy
Number of subjects: 35
Study 22275444 — intervention group
Group type: COMPARATOR
Intervention: Metformin added to oral therapy
Number of subjects: 35
Study 22275444 — intervention group
Group type: COMPARATOR
Intervention: Metformin added to insulin therapy
Number of subjects: 35
Study 22275444 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher doses of metformin
Number of subjects: 35
Study 21242609 — intervention group
Group type: EXPERIMENTAL
Intervention: 08:00 hr
Number of subjects: 20
Study 21242609 — intervention group
Group type: EXPERIMENTAL
Intervention: 14:00 hr
Number of subjects: 20
Study 17652651 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib 25 mg daily
Number of subjects: 2434
Study 17652651 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2434
Study 16620045 — intervention group
Group type: EXPERIMENTAL
Intervention: Horsechestnut seed extract
Number of subjects: 54
Study 16620045 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 12873288 — intervention group
Group type: EXPERIMENTAL
Intervention: Felted foam therapy
Number of subjects: 54
Study 12873288 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 54
Study 10978026 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical intervention (carotid endarterectomy)
Number of subjects: 659
Study 10978026 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 659
Study 10978026 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed endarterectomy
Number of subjects: 659
Study 10978026 — intervention group
Group type: COMPARATOR
Intervention: Continued medical therapy
Number of subjects: 659
Study 8791952 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg o.m. plus clarithromycin 250 mg b.d. and tinidazole 500 mg b.d. (group A)
Number of subjects: 100
Study 8791952 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg o.m. plus clarithromycin 250 mg b.d. and amoxycillin 1000 mg b.d. (group B)
Number of subjects: 100
Study 8791952 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 100
Study 8791952 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A
Number of subjects: 100
Study 8791952 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B
Number of subjects: 100
Study 1298088 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinine, quinidine, and cinchonine combination (600 mg regimen)
Number of subjects: 13
Study 1298088 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinine, quinidine, and cinchonine combination (400 mg regimen)
Number of subjects: 13
Study 1298088 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinine, quinidine, and cinchonine combination
Number of subjects: 13
Study 6098221 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic acyclovir (ACV) therapy
Number of subjects: 43
Study 6098221 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 6098221 — intervention group
Group type: COMPARATOR
Intervention: Systemic placebo
Number of subjects: 43
Study 31408480 — intervention group
Group type: EXPERIMENTAL
Intervention: Algorithm based on clinical course for SJS/TEN, medical encounters for mucocutaneous lesions from SJS/TEN, and items to exclude paraneoplastic pemphigus (not using ICD-10 codes)
Number of subjects: 113
Study 31408480 — intervention group
Group type: COMPARATOR
Intervention: Control group (randomly sampled patients)
Number of subjects: 113
Study 28947725 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy accompanied by oral anticoagulation (OAC) - triple therapy
Number of subjects: 0
Study 28947725 — intervention group
Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 0
Study 26398126 — intervention group
Group type: EXPERIMENTAL
Intervention: Low injection speed (60 seconds)
Number of subjects: 32
Study 26398126 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow injection speed (100 seconds)
Number of subjects: 32
Study 23660098 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulinastatin (UTI) 30 kU three times per day for 5 days
Number of subjects: 60
Study 23660098 — intervention group
Group type: COMPARATOR
Intervention: Routine treatment
Number of subjects: 60
Study 20872022 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic sigmoid resection (LSR)
Number of subjects: 104
Study 20872022 — intervention group
Group type: COMPARATOR
Intervention: Open sigmoid resection (OSR)
Number of subjects: 104
Study 19478249 — intervention group
Group type: EXPERIMENTAL
Intervention: RDTs plus training, guidelines, and supervision (TGS)
Number of subjects: 1540
Study 19478249 — intervention group
Group type: COMPARATOR
Intervention: TGS alone
Number of subjects: 1540
Study 18040832 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral drugs that penetrate the blood-brain barrier (CNS penetration drugs)
Number of subjects: 0
Study 18040832 — intervention group
Group type: COMPARATOR
Intervention: Non-penetrating antiretrovirals
Number of subjects: 0
Study 14711748 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic hysterectomy
Number of subjects: 1346
Study 14711748 — intervention group
Group type: COMPARATOR
Intervention: Vaginal hysterectomy
Number of subjects: 1346
Study 14711748 — intervention group
Group type: COMPARATOR
Intervention: Abdominal hysterectomy
Number of subjects: 1346
Study 11700909 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate free recall under articulatory suppression
Number of subjects: 0
Study 11700909 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate free recall after an intervening distractor task
Number of subjects: 0
Study 11700909 — intervention group
Group type: EXPERIMENTAL
Intervention: Serial position functions in semantically cued recall
Number of subjects: 0
Study 9154765 — intervention group
Group type: EXPERIMENTAL
Intervention: Cellular telephones (one analogue and four digital) tested in maximal power mode
Number of subjects: 980
Study 9154765 — intervention group
Group type: EXPERIMENTAL
Intervention: Cellular telephones (one analogue and four digital) held over the pacemaker
Number of subjects: 980
Study 9154765 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-chamber pacemakers
Number of subjects: 980
Study 9154765 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-chamber pacemakers
Number of subjects: 980
Study 9154765 — intervention group
Group type: EXPERIMENTAL
Intervention: Pacemakers without feed-through filters
Number of subjects: 980
Study 9154765 — intervention group
Group type: EXPERIMENTAL
Intervention: Pacemakers with feed-through filters
Number of subjects: 980
Study 7899001 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose of Tiapride
Number of subjects: 10
Study 7899001 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose of Tiapride
Number of subjects: 10
Study 7899001 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up observation without medication
Number of subjects: 10
Study 7899001 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiapride (general)
Number of subjects: 10
Study 3674234 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspartame
Number of subjects: 30
Study 3674234 — intervention group
Group type: COMPARATOR
Intervention: Sucrose
Number of subjects: 30
Study 3674234 — intervention group
Group type: COMPARATOR
Intervention: Glucose
Number of subjects: 30
Study 3674234 — intervention group
Group type: COMPARATOR
Intervention: Saccharin
Number of subjects: 30
Study 31934811 — intervention group
Group type: EXPERIMENTAL
Intervention: Acidic 30% hydrogen peroxide (HP)
Number of subjects: 20
Study 31934811 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutral 30% hydrogen peroxide (HP)
Number of subjects: 20
Study 31934811 — intervention group
Group type: EXPERIMENTAL
Intervention: Alkaline 30% hydrogen peroxide (HP)
Number of subjects: 20
Study 31934811 — intervention group
Group type: COMPARATOR
Intervention: Distilled water (Control)
Number of subjects: 20
Study 30173161 — intervention group
Group type: EXPERIMENTAL
Intervention: Cloxacillin
Number of subjects: 300
Study 30173161 — intervention group
Group type: COMPARATOR
Intervention: Cefazolin
Number of subjects: 300
Study 27411482 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab (IFX) + naproxen (NPX)
Number of subjects: 150
Study 27411482 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO) + naproxen (NPX)
Number of subjects: 150
Study 25393414 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychodynamic group art therapy plus treatment as usual
Number of subjects: 58
Study 25393414 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment alone
Number of subjects: 58
Study 24330706 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical training (aerobic training, 5 times a week, for 50 minutes)
Number of subjects: 100
Study 24330706 — intervention group
Group type: COMPARATOR
Intervention: Relaxation sessions (5 times a week, for 50 minutes)
Number of subjects: 100
Study 24330706 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical training
Number of subjects: 100
Study 24330706 — intervention group
Group type: COMPARATOR
Intervention: Relaxation sessions
Number of subjects: 100
Study 20429738 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured home visit by GP and district nurse one week after discharge followed by two contacts after three and eight weeks
Number of subjects: 331
Study 20429738 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 331
Study 20429738 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured home visit by GP and district nurse
Number of subjects: 331
Study 18831691 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose folate supplementation (5 mg daily)
Number of subjects: 467
Study 18831691 — intervention group
Group type: EXPERIMENTAL
Intervention: High baseline folate levels
Number of subjects: 467
Study 18831691 — intervention group
Group type: EXPERIMENTAL
Intervention: High parasite densities
Number of subjects: 467
Study 18831691 — intervention group
Group type: EXPERIMENTAL
Intervention: Age <20 years
Number of subjects: 467
Study 18831691 — intervention group
Group type: COMPARATOR
Intervention: Low-/moderate-dose folate supplementation
Number of subjects: 467
Study 16939028 — intervention group
Group type: EXPERIMENTAL
Intervention: Er,Cr:YSGG laser irradiation
Number of subjects: 32
Study 16939028 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 laser irradiation
Number of subjects: 32
Study 16939028 — intervention group
Group type: COMPARATOR
Intervention: Control for Er,Cr:YSGG
Number of subjects: 32
Study 16939028 — intervention group
Group type: COMPARATOR
Intervention: Control for CO2
Number of subjects: 32
Study 12923794 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-existential group therapy (CEGT)
Number of subjects: 303
Study 12923794 — intervention group
Group type: COMPARATOR
Intervention: Control (3 relaxation classes)
Number of subjects: 303
Study 11153576 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate (MF) dry powder inhaler (DPI) 200 microg b.i.d
Number of subjects: 0
Study 11153576 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate (MF) dry powder inhaler (DPI) 400 microg b.i.d
Number of subjects: 0
Study 11153576 — intervention group
Group type: COMPARATOR
Intervention: Budesonide (BUD) Turbuhaler 400 microg b.i.d
Number of subjects: 0
Study 11153576 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 0
Study 9298773 — intervention group
Group type: EXPERIMENTAL
Intervention: Static stretching
Number of subjects: 59
Study 9298773 — intervention group
Group type: EXPERIMENTAL
Intervention: Ballistic stretching
Number of subjects: 59
Study 9298773 — intervention group
Group type: EXPERIMENTAL
Intervention: Stationary cycling
Number of subjects: 59
Study 9298773 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 59
Study 9298773 — intervention group
Group type: COMPARATOR
Intervention: Control group (resting)
Number of subjects: 59
Study 8262577 — intervention group
Group type: EXPERIMENTAL
Intervention: Loading dose diazepam (67 +/- 9.3 mg)
Number of subjects: 41
Study 8262577 — intervention group
Group type: COMPARATOR
Intervention: Conventional dose diazepam (200 mg)
Number of subjects: 41
Study 3516189 — intervention group
Group type: EXPERIMENTAL
Intervention: promethazine 0.5 mg kg‐1 i.m. 45 min before induction of anaesthesia
Number of subjects: 60
Study 3516189 — intervention group
Group type: EXPERIMENTAL
Intervention: cimetidine 400 mg i.m. 120 min before induction
Number of subjects: 60
Study 3516189 — intervention group
Group type: COMPARATOR
Intervention: Control group (no premedication)
Number of subjects: 60
Study 29445881 — intervention group
Group type: EXPERIMENTAL
Intervention: Salivary and serum vaspin (VASP) concentrations
Number of subjects: 90
Study 29445881 — intervention group
Group type: EXPERIMENTAL
Intervention: Total antioxidant status (TAS)
Number of subjects: 90
Study 29445881 — intervention group
Group type: EXPERIMENTAL
Intervention: Salivary flow
Number of subjects: 90
Study 29445881 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlations between TAS, VASP, salivary flow, and nutritional status
Number of subjects: 90
Study 29445881 — intervention group
Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 90
Study 28281845 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS (2 mA for 20 min over left prefrontal cortex)
Number of subjects: 16
Study 28281845 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 16
Study 26181573 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga practice (90 minutes once a week for 12 weeks, plus daily home practice for 40 minutes)
Number of subjects: 25
Study 22887494 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin plus glycoprotein platelet inhibitors (GPI)
Number of subjects: 13819
Study 22887494 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin plus GPI
Number of subjects: 13819
Study 22887494 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin alone
Number of subjects: 13819
Study 22887494 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-US sites)
Number of subjects: 13819
Study 22322057 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct dissection of urogenital diaphragm
Number of subjects: 126
Study 22322057 — intervention group
Group type: COMPARATOR
Intervention: Traditional operative method
Number of subjects: 126
Study 17939042 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN alpha + Ribavirin + 2 g Carnitine per day (group B)
Number of subjects: 70
Study 17939042 — intervention group
Group type: COMPARATOR
Intervention: IFN alpha + Ribavirin (group A)
Number of subjects: 70
Study 16783280 — intervention group
Group type: EXPERIMENTAL
Intervention: Genuine acupuncture to LI4 (Hegu) and LI10 (Shousanli) for 20 minutes
Number of subjects: 35
Study 16783280 — intervention group
Group type: EXPERIMENTAL
Intervention: Inappropriate acupuncture to PC3 (Quze) and PC6 (Neiguan) for 20 minutes
Number of subjects: 35
Study 16783280 — intervention group
Group type: COMPARATOR
Intervention: No intervention control for 20 minutes
Number of subjects: 35
Study 12837144 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil (cholinesterase inhibitor)
Number of subjects: 1
Study 10741710 — intervention group
Group type: EXPERIMENTAL
Intervention: GM2-KLH/QS21 vaccine at GM2 doses of 1, 3, 10, 30, or 70 microg
Number of subjects: 52
Study 10741710 — intervention group
Group type: EXPERIMENTAL
Intervention: GM2-KLH/QS21 vaccine at 30 microg dose
Number of subjects: 52
Study 10741710 — intervention group
Group type: EXPERIMENTAL
Intervention: GM2-KLH/QS21 vaccine (doses of 3-70 microg)
Number of subjects: 52
Study 10741710 — intervention group
Group type: COMPARATOR
Intervention: Previous vaccine formulation (GM2 and bacille Calmette-Guerin)
Number of subjects: 52
Study 9007133 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel 225 mg/m2 via 1-hour infusion and carboplatin (AUC 6.0)
Number of subjects: 100
Study 9007133 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel 135 mg/m2 via 1-hour infusion, cisplatin 60 mg/m2, etoposide 100 mg/m2 (induction chemotherapy) followed by radiation therapy and concurrent chemotherapy
Number of subjects: 100
Study 1627202 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertaconazole 1% cream, twice a day for 28 days
Number of subjects: 20
Study 1627202 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertaconazole 2% cream, twice a day for 28 days
Number of subjects: 20
Study 1627202 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 20
Study 6729761 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicergoline 30 mg + placebo
Number of subjects: 12
Study 6729761 — intervention group
Group type: COMPARATOR
Intervention: Acebutolol 200 mg + placebo
Number of subjects: 12
Study 6729761 — intervention group
Group type: COMPARATOR
Intervention: Acebutolol 400 mg + placebo
Number of subjects: 12
Study 6729761 — intervention group
Group type: EXPERIMENTAL
Intervention: Acebutolol 200 mg + nicergoline 15 mg
Number of subjects: 12
Study 6729761 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 6729761 — intervention group
Group type: COMPARATOR
Intervention: Nicergoline
Number of subjects: 12